1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: generic
Realcan Pharmaceutical Group Co., Ltd. Class A

Realcan Pharmaceutical Group Co., Ltd. Class A

SSZSE:002589
2.90
CNY
+0.05
(+1.75%)
0.04EPS
191.38P/E
3.70BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
6.73
7.86
7.91
11.55
15.48
22.87
23.56
18.76
14.45
8.34
5.34
6.48
4.54
4.78
Basic EPS, GAAP
0.16
0.18
0.19
0.44
0.67
0.52
-0.62
0.18
0.09
-1.24
0.01
0.01
0.01
0.01
Free Cash Flow per Basic Share
-0.49
-0.35
-0.47
-1.54
-1.87
-0.55
0.77
-0.16
-0.01
0.24
-0.14
0.04
-0.01
- -
Dividend per Share
0.08
0.08
0.08
0.08
0.15
0.35
0.33
0.24
0.22
0.1
0.13
0.16
0.11
0.07
Book Value per Share
1.63
1.79
2.5
4.57
5.19
5.64
4.78
4.96
5.03
3.59
3.62
3.69
3.52
3.53
Tangible Book Value per Share
1.54
1.66
2.08
3.52
2.61
3.33
3.79
4.21
4.29
3.08
3.16
3.28
3.07
3.09
Basic Weighted Avg Shares
880
991
1,233
1,352
1,505
1,483
1,496
1,452
1,458
1,477
1,505
1,229
1,607
1,483
Sales/Revenue/Turnover
5,926
7,786
9,750
15,619
23,294
33,919
35,259
27,234
21,060
12,311
8,034
7,967
7,296
7,091
Operating Margin (%)
4.61
4.19
4.31
6.61
8.18
8.38
7.36
5.93
4.91
0.55
-0.81
0.82
0.93
0.63
Depreciation Expense
12
24
43
79
147
234
275
291
319
284
220
199
179
- -
Net Income, GAAP
144
181
236
591
1,008
771
-928
261
131
-1,831
20
12
16
19
Effective Tax Rate (%)
25.46
24.82
23.65
23.12
24.41
35.08
524.89
31.75
17.85
- -
- -
1.89
- -
- -
Profit Margin (%)
2.42
2.32
2.42
3.78
4.33
2.27
-2.63
0.96
0.62
-14.87
0.25
0.15
0.22
0.27
Working Capital
1,186
1,196
1,995
4,696
5,461
7,464
7,097
5,383
4,164
351
778
1,140
791
788
LT Debt
- -
- -
- -
- -
1,667
2,132
1,326
24
88
70
262
331
236
217
Total Equity
1,650
1,825
3,404
7,503
9,674
11,338
10,253
10,515
9,693
5,751
5,637
5,709
5,423
5,451
Return on Invested Capital (%)
7.12
6.31
5.89
9.28
11.18
7.47
-3.06
3.54
2.43
- -
- -
0.12
- -
- -
Return on Capital (%)
9.42
8.43
7.32
8.15
6.52
3.81
-25.4
1.63
1.97
- -
- -
1.49
- -
- -
Return on Common Equity (%)
11.27
10.55
9.45
11.73
13.73
9.47
-11.84
3.57
1.74
-28.22
0.37
0.22
0.3
0.35

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
4,369
4,640
4,961
LT Borrowings
235
398
215
LT Finance Leases
1
2
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,505
1,505
1,505
Market Capitalization
4,845
4,695
3,702

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,453
10,605
11,023
Cash, Cash Equivalents & STI
3,745
5,050
5,752
Accounts Receivable, Net
3,711
3,813
3,606
Inventories
715
652
631
Total Current Liabilities
8,662
9,656
10,234
Payables & Accruals
- -
- -
- -
ST Debt
4,369
4,640
4,961
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
10.53%
-10.84%
-5.01%
Free Cash Flow
-268.09%
-508.88%
-126.54%
Net Income, GAAP
-180.63%
-331.08%
30.73%
Sales/Revenue/Turnover
2.79%
-21.64%
-8.42%
Total Cash Common Dividend
17.22%
-8.58%
-12.28%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,019
2,013
2,025
1,910
7,967
2025
1,757
1,787
- -
1,889
7,296
2026
1,707
1,707
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.01
0.01
-0.01
0.01
2025
0.01
- -
- -
- -
0.01
2026
0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
0.03
0.04
0.02
0.16
2025
0.05
0.03
- -
0.01
0.11
2026
0.05
-0.02
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Xu Han
Full Time Employees
2,897
Sector
Health technology
Industry
Pharmaceuticals: generic
Address
Building 13 Yantai SD China 264001
IPO Date
May 31, 2011
Website
realcan.cn
Similar Companies
Teva Pharmaceutical Industries Limited (NYSE:TEVA)
Teva Pharmaceutical Industries Limited (TASE:TEVA)
Jagsonpal Pharmaceuticals Ltd. (NSE:JAGSNPHARM)
Zim Laboratories Ltd. (NSE:ZIMLAB)
Paradigm Biopharmaceuticals Ltd. (ASX:PAR)
Neuren Pharmaceuticals Limited (ASX:NEU)
Business
Realcan Pharmaceutical Group Co., Ltd. Realcan Pharmaceutical Group Co., Ltd. (002589.SZ) operates as a comprehensive medical service provider in China, primarily engaged in the distribution of pharmaceuticals, medical devices, and medical consumables to medical institutions nationwide. The company offers an extensive range of products including psychotropic substances, narcotic drugs, antibiotics, innovative drugs, biochemical pharmaceuticals, biological products, chemical drug materials, chemical preparations, traditional Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, and granules; it also provides services across segments such as drug and device distribution, in vitro diagnostics covering laboratory biochemistry, immunity, and clinical examination, digital medical solutions including one-stop health management platforms, pharmaceutical logistics with third-party services, academic promotion, hospital management consulting, medical diagnosis, equipment research and development, production, and financial technology. Its sales network spans 31 provinces and cities, directly serving nearly 60,000 medical institutions and supporting leading domestic and foreign manufacturers. Founded in 2004 and headquartered in Yantai, Shandong Province, the company listed on the Shenzhen Stock Exchange in June 2011 and changed its name from Realcan Pharmaceutical Co., Ltd. to its current form in December 2018. Recent developments include an ongoing share repurchase program initiated in 2024, with tranches completed through November 2025 repurchasing over 1% of shares for approximately CNY 75 million to stabilize market confidence; in June 2024, it formed a strategic joint venture with Meiyitain Biotechnology (Wuhan) Co., Ltd., Shandong Ruikang Microecology Engineering Co., Ltd., to develop fecal microbiota transplantation technologies, establishing production centers and clinical services for conditions like autism; additionally, it continues expansions in digital transformation projects, such as cloud computing initiatives and selection for provincial service industry development funds in 2023-2024, alongside school-enterprise partnerships like the April 2024 collaboration with Yantai Preschool Normal College for training bases.